These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 26180485)

  • 1. Idiopathic Macular Telangiectasia Type 1 with Ruptured Retinal Arterial Macroaneurysm Post Intravitreal Bevacizumab.
    Nakhwa CP; Sindal MD
    Middle East Afr J Ophthalmol; 2015; 22(3):396-8. PubMed ID: 26180485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of ruptured retinal arterial macroaneurysm with intravitreal bevacizumab.
    Javey G; Moshfeghi AN; Moshfeghi AA
    Ophthalmic Surg Lasers Imaging; 2010; 41(4):1-5. PubMed ID: 21728252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravitreal bevacizumab for macular complications from retinal arterial macroaneurysms.
    Pichi F; Morara M; Torrazza C; Manzi G; Alkabes M; Balducci N; Vitale L; Lembo A; Ciardella AP; Nucci P
    Am J Ophthalmol; 2013 Feb; 155(2):287-294.e1. PubMed ID: 23111179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined treatment with intravitreal bevacizumab and laser photocoagulation for exudative maculopathy in facioscapulohumeral muscular dystrophy.
    Matos R; Beato J; Silva M; Silva S; Brandão E; Falcão-Reis F; Penas S
    Ophthalmic Genet; 2017; 38(5):490-493. PubMed ID: 28121209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dexamethasone implant for the treatment of edema related to idiopathic macular telangiectasia.
    Sandali O; Akesbi J; Rodallec T; Laroche L; Nordmann JP
    Can J Ophthalmol; 2013 Aug; 48(4):e78-80. PubMed ID: 23931489
    [No Abstract]   [Full Text] [Related]  

  • 6. Intravitreal bevacizumab for type 2 idiopathic macular telangiectasia.
    Veloso CE; Vianna RN; Pelayes DE; Nehemy MB
    Ophthalmic Res; 2013; 49(4):205-8. PubMed ID: 23364325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravitreal bevacizumab therapy for idiopathic macular telangiectasia.
    Matsumoto Y; Yuzawa M
    Jpn J Ophthalmol; 2010 Jul; 54(4):320-4. PubMed ID: 20700800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravitreal bevacizumab for macular edema from idiopathic juxtafoveal retinal telangiectasis.
    Moon SJ; Berger AS; Tolentino MJ; Misch DM
    Ophthalmic Surg Lasers Imaging; 2007; 38(2):164-6. PubMed ID: 17396701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long term result of intravitreal bevacizumab in a patient newly transformed to proliferative macular telangiectasia type 2.
    Ozkaya A; Alkin Z; Karakucuk Y; Yazici AT; Demirok A
    Middle East Afr J Ophthalmol; 2013; 20(4):360-2. PubMed ID: 24339691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion.
    Ding X; Li J; Hu X; Yu S; Pan J; Tang S
    Retina; 2011 May; 31(5):838-45. PubMed ID: 21293319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retinal Macroaneurysm Associated with Congenital Anomalous Retinal Artery.
    Kumar V; Agarwal R; Chandra P
    Optom Vis Sci; 2017 Jul; 94(7):781-785. PubMed ID: 28609419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of ruptured retinal arterial macroaneurysm with intravitreal bevacizumab.
    Javey G; Moshfeghi AN; Moshfeghi AA
    Ophthalmic Surg Lasers Imaging; 2010 Aug; 41 Online():e1-5. PubMed ID: 21155520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of intravitreal bevacizumab injections to treat type 1 idiopathic macular telangiectasia.
    Moon BG; Kim YJ; Yoon YH; Lee JY
    Graefes Arch Clin Exp Ophthalmol; 2012 Nov; 250(11):1697-9. PubMed ID: 21863255
    [No Abstract]   [Full Text] [Related]  

  • 14. Intravitreal bevacizumab for treatment of proliferative and nonproliferative type 2 idiopathic macular telangiectasia.
    Roller AB; Folk JC; Patel NM; Boldt HC; Russell SR; Abramoff MD; Mahajan VB
    Retina; 2011 Oct; 31(9):1848-55. PubMed ID: 21610563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LONG-TERM OUTCOMES OF INTRAVITREAL BEVACIZUMAB THERAPY FOR SUBRETINAL NEOVASCULARIZATION SECONDARY TO IDIOPATHIC MACULAR TELANGIECTASIA TYPE 2.
    Toygar O; Guess MG; Youssef DS; Miller DM
    Retina; 2016 Nov; 36(11):2150-2157. PubMed ID: 27258671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of intravitreal bevacizumab combined with focal laser photocoagulation in the case of macular telangiectasia type 2 with retinal arterial macroaneurysm.
    Demir G; Artunay Ö; Sucu ME; Demircan A; Yaşa D; Alagöz C; Öcal MC
    Lasers Med Sci; 2019 Mar; 34(2):427-430. PubMed ID: 30027424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema.
    Kook D; Wolf A; Kreutzer T; Neubauer A; Strauss R; Ulbig M; Kampik A; Haritoglou C
    Retina; 2008 Oct; 28(8):1053-60. PubMed ID: 18779710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravitreal bevacizumab for symptomatic retinal arterial macroaneurysm.
    Cho HJ; Rhee TK; Kim HS; Han JI; Lee DW; Cho SW; Kim JW
    Am J Ophthalmol; 2013 May; 155(5):898-904. PubMed ID: 23385203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravitreal bevacizumab combined with grid photocoagulation in recurrent macular edema secondary to retinal vein occlusion.
    Farese E; Cennamo G; Velotti N; Traversi C; Rinaldi M; De Crecchio G
    Eur J Ophthalmol; 2014; 24(5):761-70. PubMed ID: 24585424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema.
    Haritoglou C; Kook D; Neubauer A; Wolf A; Priglinger S; Strauss R; Gandorfer A; Ulbig M; Kampik A
    Retina; 2006; 26(9):999-1005. PubMed ID: 17151486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.